Home › Funds › Logos Global Management LP › MLTX
Logos Global Management LP position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Logos Global Management LP reported holding 2,675,000 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$52.1M, representing 2.24% of its reported portfolio and ranking #15 among its reported holdings. Logos Global Management LP has disclosed MLTX holdings in 7 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Logos Global Management LP's MLTX position evolved
Logos Global Management LP first disclosed a stake in MLTX in Q4 2023 at 150,000 shares (US$9.1M). The position peaked in Q2 2026 at 2,675,000 shares, worth US$52.1M. Across 7 filings, Logos Global Management LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,675,000 shares valued at US$52.1M — an increase of 1,175,000 shares quarter over quarter.. Notable position changes include a 43% trim in Q2 2025 (shares fell 85% over the following quarter), a 78% increase in Q2 2026 (shares fell 40% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 150.00K | $9.06M | New |
| Q2 2024 | 750.00K | $32.98M | New |
| Q1 2025 | 350.00K | $13.67M | New |
| Q2 2025 | 200.00K | $9.44M | Reduce |
| Q4 2025 | 1.75M | $23.07M | New |
| Q1 2026 | 1.50M | $27.96M | Reduce |
| Q2 2026 | 2.67M | $52.08M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 29 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on Logos Global Management LP
FAQ
How long has Logos Global Management LP held MLTX?
Logos Global Management LP has disclosed MLTX holdings in 7 of the last 11 reported quarters, going back to Q4 2023.
What is Logos Global Management LP's current position in MLTX?
As of Q2 2026, Logos Global Management LP holds 2.67M shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $52.08M, representing 2.24% of its reported portfolio and ranking #15.
Has Logos Global Management LP been buying or selling MLTX?
In the latest 13F filing (Q2 2026), Logos Global Management LP increased its position in MLTX. The position peaked in Q2 2026 at 2.67M shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.